ABVC BioPharma (NASDAQ:ABVC) Announces Quarterly Earnings Results

ABVC BioPharma (NASDAQ:ABVC) released its quarterly earnings data on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, FiscalAI reports.

ABVC BioPharma Stock Performance

Shares of NASDAQ:ABVC opened at $1.07 on Tuesday. The stock has a market capitalization of $27.22 million, a price-to-earnings ratio of -2.68 and a beta of 0.42. ABVC BioPharma has a 1-year low of $0.88 and a 1-year high of $5.48. The company’s fifty day moving average is $1.20 and its two-hundred day moving average is $1.84.

Hedge Funds Weigh In On ABVC BioPharma

Several large investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new position in shares of ABVC BioPharma in the third quarter worth about $60,000. Citadel Advisors LLC purchased a new stake in shares of ABVC BioPharma in the third quarter worth approximately $48,000. Finally, Geode Capital Management LLC raised its position in ABVC BioPharma by 7.7% during the fourth quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock valued at $431,000 after acquiring an additional 14,553 shares in the last quarter. Institutional investors own 11.38% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.